Vanguard Group’s Biocept, Inc. BIOC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-20,599
| Closed | -$328K | – | 4591 |
|
|
2022
Q4 | $328K | Buy |
20,599
+12
| +0.1% | +$265 | ﹤0.01% | 4204 |
|
|
2022
Q3 | $569K | Sell |
20,587
-1,269
| -6% | -$37.5K | ﹤0.01% | 4179 |
|
|
2022
Q2 | $616K | Hold |
21,856
| – | – | ﹤0.01% | 4230 |
|
|
2022
Q1 | $1.52M | Hold |
21,856
| – | – | ﹤0.01% | 4066 |
|
|
2021
Q4 | $2.37M | Sell |
21,856
-97
| -0.4% | -$11.2K | ﹤0.01% | 3979 |
|
|
2021
Q3 | $2.64M | Hold |
21,953
| – | – | ﹤0.01% | 3972 |
|
|
2021
Q2 | $2.76M | Sell |
21,953
-288
| -1% | -$39K | ﹤0.01% | 3868 |
|
|
2021
Q1 | $3.4M | Hold |
22,241
| – | – | ﹤0.01% | 3710 |
|
|
2020
Q4 | $2.96M | Buy |
22,241
+421
| +2% | +$60K | ﹤0.01% | 3556 |
|
|
2020
Q3 | $2.89M | Buy |
21,820
+228
| +1% | +$46.1K | ﹤0.01% | 3380 |
|
|
2020
Q2 | $4.61M | Buy |
21,592
+19,984
| +1,243% | +$2.87M | ﹤0.01% | 3135 |
|
|
2020
Q1 | $128K | Buy |
1,608
+1,088
| +209% | +$111K | ﹤0.01% | 3914 |
|
|
2019
Q4 | $45K | Hold |
520
| – | – | ﹤0.01% | 4052 |
|
|
2019
Q3 | $127K | Hold |
520
| – | – | ﹤0.01% | 4011 |
|
|
2019
Q2 | $173K | Buy |
520
+269
| +107% | +$85.2K | ﹤0.01% | 3999 |
|
|
2019
Q1 | $86K | Buy |
251
+205
| +446% | +$83K | ﹤0.01% | 4024 |
|
|
2018
Q4 | $12K | Sell |
46
-20
| -30% | -$10K | ﹤0.01% | 4140 |
|
|
2018
Q3 | $55K | Sell |
66
-36
| -35% | -$45.9K | ﹤0.01% | 4121 |
|
|
2018
Q2 | $184K | Sell |
102
-3
| -3% | -$6.07K | ﹤0.01% | 3986 |
|
|
2018
Q1 | $278K | Buy |
105
+19
| +22% | +$71.3K | ﹤0.01% | 3908 |
|
|
2017
Q4 | $536K | Hold |
86
| – | – | ﹤0.01% | 3729 |
|
|
2017
Q3 | $950K | Buy |
86
+1
| +1% | +$11.8K | ﹤0.01% | 3603 |
|
|
2017
Q2 | $1.05M | Buy |
85
+7
| +9% | +$98.9K | ﹤0.01% | 3557 |
|
|
2017
Q1 | $1.49M | Buy |
78
+53
| +212% | +$901K | ﹤0.01% | 3468 |
|
|
2016
Q4 | $174K | Buy |
25
+9
| +56% | +$75.3K | ﹤0.01% | 3914 |
|
|
2016
Q3 | $227K | Buy |
16
+1
| +7% | +$16.3K | ﹤0.01% | 3884 |
|
|
2016
Q2 | $273K | Buy |
15
+1
| +7% | +$24.2K | ﹤0.01% | 3895 |
|
|
2016
Q1 | $492K | Buy |
14
+3
| +27% | +$114K | ﹤0.01% | 3793 |
|
|
2015
Q4 | $404K | Buy |
11
+1
| +10% | +$53.1K | ﹤0.01% | 3885 |
|
|
2015
Q3 | $633K | Buy |
10
+1
| +11% | +$62.5K | ﹤0.01% | 3783 |
|
|
2015
Q2 | $591K | Buy |
9
+1
| +13% | +$76.8K | ﹤0.01% | 3817 |
|
|
2015
Q1 | $482K | Buy |
8
+7
| +700% | +$470K | ﹤0.01% | 3839 |
|
|
2014
Q4 | $73K | Hold |
1
| – | – | ﹤0.01% | 4002 |
|
|
2014
Q3 | $72K | Hold |
1
| – | – | ﹤0.01% | 3981 |
|
|
2014
Q2 | $177K | Hold |
1
| – | – | ﹤0.01% | 3869 |
|
|
2014
Q1 | $205K | Buy |
+1
| New | +$226K | ﹤0.01% | 3816 |
|
Other funds holding BIOC
BCM
HF
SM
TMWM
Vanguard Group's BIOC Position: Q1 2023 in Review
Vanguard Group sold out of Biocept, Inc. (BIOC) in Q1 2023, closing a stake of 20,599 shares — an estimated $328K sold.
Vanguard Group first reported a position in BIOC in Q1 2014 and held it in 36 quarters. The position peaked at $4.61M in Q2 2020. 25 funds tracked by Wall St. Rank hold BIOC as of Q1 2023.
- Vanguard Group reported no remaining Biocept, Inc. position as of Q1 2023 after selling out during the quarter.
- Vanguard Group sold 20,599 Biocept, Inc. shares in Q1 2023, an estimated $328K.
- Vanguard Group first reported a position in Biocept, Inc. in Q1 2014 and held it in 36 quarters.
- Vanguard Group's Biocept, Inc. position peaked at $4.61M in Q2 2020.
- 25 funds tracked by Wall St. Rank held Biocept, Inc. as of Q1 2023.
Based on Vanguard Group's 13F filing for Q1 2023, filed 15 May 2023.